Loading
A phase 1 trial of CYNK-001 run by Celularity Incorporated, terminated.
Natural Killer Cell (CYNK-001) IV Infusion or IT Administration in Adults With Recurrent GBM is a phase 1 interventional study registered as NCT04489420 by Celularity Incorporated, with 3 participants enrolled, started 2020-10-01. Conditions recorded: Astrocytoma, Grade IV, Giant Cell Glioblastoma, Glioblastoma Multiforme, Cyclophosphamide, Immunosuppressive Agents, Immunologic Factors, Physiological Effects of Drugs, Molecular Mechanisms of Pharmacological Action, Antiviral Agents, Anti-infective Agents, Analgesics, Non-narcotic, Analgesics, Sensory System Agents and Peripheral Nervous System Agents. Interventions recorded: CYNK001-IV and CYNK001-IT.
Shares CYNK-001, Celularity, Brain and spinal cord tumours (all types), Glioma & glioblastoma and the tag pipeline.
Shares CYNK-001, Celularity and the tag pipeline.
Shares CYNK-001, Celularity and the tag pipeline.
Shares Brain and spinal cord tumours (all types), Glioma & glioblastoma and the tag pipeline.
Shares Brain and spinal cord tumours (all types), Glioma & glioblastoma and the tag pipeline.
Shares Brain and spinal cord tumours (all types), Glioma & glioblastoma and the tag pipeline.
Shares Brain and spinal cord tumours (all types), Glioma & glioblastoma and the tag pipeline.
Shares Brain and spinal cord tumours (all types), Glioma & glioblastoma and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/